Investor Presentaiton

Key operational highlights (1/2) . Record H1 on revenues, profits and cash generation, continuing the positive trends seen in Q1 2021 Strong performance of Core Business¹ with rapidly accelerating, strong growth across business lines: • H1 2021: 17% organic growth² Q2 2021: 25% organic growth³ О Now largely recovered EUR 250m revenues lost due to COVID impacts in FY 2020, earlier than forecast Further notable product launches and continued innovation across business lines, including: * eurofins O Highly innovative rapid testing methods including for the identification of sugars and the certification of organic products New proprietary advanced testing methods to expand Clinical Diagnostics' services for transplant patients Differentiated services/ technologies in Environment Testing including a new automated and robotised PFAS testing method supporting the lowest detection limits globally TruGrafⓇ approved with Humana for in-network coverage of Medicare kidney transplant patients Since H1 2020 was affected by Covid, it is an easy comparable. Looking at organic growth from the pre-pandemic period, H1 2019 is a better indication of long term trends and business recovery Core Business H1 2021 organic revenue growth has been 13% compared to H1 20195 Excluding COVID-19 related clinical testing and reagent revenues 1 2 +16% vs H1 2019, close to +13% corrected for EUR 62m estimated revenue impact of cyber-attack of 2 June 2019 3 +19% vs Q2 2019, close to +13% corrected for EUR 62m estimated revenue impact of cyber-attack of 2 June 2019 4 5 Approved by the International Organization for Standardization (ISO), the European Committee for Standardization (CEN) and the International Dairy Federation (IDF) 2019 corrected for EUR 62m estimated revenue impact of cyber-attack of 2 June 2019 4

View entire presentation